metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
squamous - mNSCLC - L2 - all population metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) squamous cell - mNSCLC - L2 squamous - mNSCLC - L2 - all population
versus docetaxel
	nivolumab alone
	CheckMate 017, 2015 J Thorac Oncol 2018; 13:194-204 J. Clin. Oncol. 2017; 35:3924-3933 N. Engl. J. Med. 2015; 373:123-35 J Clin Oncol 2021 Mar 1;39(7):723-733. NCT01642004	RCT	squamous - mNSCLC - L2 - all population	Nivolumab	Docetaxel	Patients with stage IIIB or IV squamous-cell NSCLC who had disease recurrence after only one prior platinum-containing regimen	135 / 137	some concern	conclusif	demonstrated 41 % decrease in deaths (OS) (PE) demonstrated 38 % decrease in progression or deaths (PFS) (PE) suggested 69 % decrease in deaths (OS) (extension) suggested 52 % decrease in PFS (extension) more...